0001493152-22-025666 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover - shares	9 Months Ended
Cover - shares	Jul. 31, 2022	Sep. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--10-31
Entity File Number	001-36138
Entity Registrant Name	ADVAXIS, INC.
Entity Central Index Key	0001100397
Entity Tax Identification Number	02-0563870
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9 Deer Park Drive
Entity Address, Address Line Two	Suite K-1
Entity Address, City or Town	Monmouth Junction
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08852
City Area Code	(609)
Local Phone Number	452-9813
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,815,951

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2022	Oct. 31, 2021
Current assets:
Cash and cash equivalents	$ 28,150,000	$ 41,614,000
Prepaid expenses and other current assets	1,667,000	1,643,000
Total current assets	29,817,000	43,257,000
Property and equipment (net of accumulated depreciation)	73,000	118,000
Intangible assets (net of accumulated amortization)	181,000	3,354,000
Operating right-of-use asset (net of accumulated amortization)	19,000	40,000
Other assets	11,000	11,000
Total assets	30,101,000	46,780,000
Current liabilities:
Accounts payable	90,000	87,000
Accrued expenses	1,510,000	2,836,000
Current portion of operating lease liability	19,000	28,000
Common stock warrant liability	287,000	4,929,000
Total current liabilities	1,906,000	7,880,000
Operating lease liability, net of current portion		12,000
Total liabilities	1,906,000	7,892,000
Contingencies – Note 8
Series D convertible preferred stock- $0.001 par value; 0 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.
Common stock - $0.001 par value; 170,000,000 shares authorized, 1,815,951 and 1,820,452 shares issued and outstanding at July 31, 2022 and October 31, 2021.	2,000	2,000
Additional paid-in capital	466,561,000	467,486,000
Accumulated deficit	(438,368,000)	(428,600,000)
Total stockholders’ equity	28,195,000	38,888,000
Total liabilities and stockholders’ equity	$ 30,101,000	$ 46,780,000

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jul. 31, 2022	Oct. 31, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	1,815,951	1,820,452
Common stock, shares outstanding	1,815,951	1,820,452
Series D Convertible Redeemable Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	0	0
Temporary equity, shares issued	0	0
Temporary equity, shares outstanding	0	0

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Income Statement [Abstract]
Revenue		$ 250,000	$ 250,000	$ 3,240,000
Operating expenses:
Research and development expenses	2,233,000	1,703,000	5,371,000	8,616,000
General and administrative expenses	2,053,000	2,678,000	6,331,000	9,038,000
Intangible asset impairment	3,005,000		3,005,000
Total operating expenses	7,291,000	4,381,000	14,707,000	17,654,000
Loss from operations	(7,291,000)	(4,131,000)	(14,457,000)	(14,414,000)
Other income (expense):
Interest income, net	50,000	1,000	57,000	3,000
Net changes in fair value of derivative liabilities	276,000	846,000	4,685,000	1,814,000
Other income (expense)	2,000		(3,000)	229,000
Net loss before income taxes	(6,963,000)	(3,284,000)	(9,718,000)	(12,368,000)
Income tax expense		50,000	50,000	50,000
Net loss	(6,963,000)	(3,334,000)	(9,768,000)	(12,418,000)
Accretion of discount and redemption feature of convertible preferred stock			(1,025,000)
Income available to common stockholders	$ (6,963,000)	$ (3,334,000)	$ (10,793,000)	$ (12,418,000)
Net loss per common share, basic and diluted	$ (3.83)	$ (1.83)	$ (5.93)	$ (8.04)
Weighted average number of common shares outstanding	1,817,761	1,820,452	1,819,545	1,543,927

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
OPERATING ACTIVITIES
Net loss	$ (9,768,000)	$ (12,418,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation	74,000	511,000
Gain on change in value of warrants	(4,642,000)	(1,814,000)
Gain on change in value of preferred stock redemption liability	(43,000)
Loss on disposal of property and equipment		1,530,000
Abandonment of intangible assets	159,000	90,000
Impairment charges on intangible assets	3,005,000
Depreciation expense	45,000	366,000
Amortization expense of intangible assets	210,000	203,000
Amortization of right-of-use asset	21,000	327,000
Net gain on write-off of right-of-use asset and lease liability		(116,000)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and deferred expenses	(24,000)	488,000
Other assets		171,000
Accounts payable and accrued expenses	(1,323,000)	513,000
Deferred revenue		(165,000)
Operating lease liabilities	(21,000)	(1,389,000)
Net cash used in operating activities	(12,307,000)	(11,703,000)
INVESTING ACTIVITIES
Proceeds from disposal of property and equipment		219,000
Cost of intangible assets	(201,000)	(323,000)
Net cash used in investing activities	(201,000)	(104,000)
FINANCING ACTIVITIES
Net proceeds of issuance of Series D preferred stock	4,312,000
Net proceeds of issuance of common stock and warrants		28,115,000
Fractional shares cashed out	(18,000)
Redemption of Series D preferred stock	(5,250,000)
Warrant exercises		3,771,000
Net cash (used in) provided by financing activities	(956,000)	31,886,000
Net (decrease) increase in cash and cash equivalents	(13,464,000)	20,079,000
Cash and cash equivalents at beginning of period	41,614,000	25,178,000
Cash and cash equivalents at end of period	28,150,000	45,257,000
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes	50,000	50,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock	44,000
Accretion of discount and redemption feature of convertible preferred stock	$ 1,025,000

NATURE OF OPERATIONS

9 Months Ended

Jul. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;

	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and

	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

COVID-19

On March 11, 2020, the World Health Organization characterized the outbreak of the novel coronavirus (“COVID-19”) as a global pandemic and recommended containment and mitigation measures. Since then, extraordinary actions have been taken by international, federal, state, and local public health and governmental authorities to contain and combat the outbreak and spread of COVID-19 in regions throughout the world. The continued impact of the COVID-19 pandemic cannot be predicted at this time.

Liquidity and Capital Resources

Liquidity and Management’s Plans

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

As of July 31, 2022, the Company had approximately $28.2 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

9 Months Ended

Jul. 31, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of July 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Restricted Cash

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption. On April 6, 2022, the Series D convertible preferred stock was redeemed utilizing the entire amount held in the escrow fund.

Convertible Preferred Stock

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

	2022		2021
	As of July 31,
	2022		2021
Warrants		377,818		377,818
Stock options		11,118		12,892
Total		388,936		390,710

Reverse Stock Split

On March 31, 2022, the Company’s stockholders voted to approve an amendment to allow the Company to execute a reverse stock split of common stock within a range of 1 for 20 to 1 for 80, without reducing the authorized number of shares of the common stock, at the discretion of the Board of Directors. On June 3, 2022, the Board of Directors approved a 1 for 80 reverse stock split, which became effective on June 6, 2022. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

Recent Accounting Standards

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

PROPERTY AND EQUIPMENT

9 Months Ended

Jul. 31, 2022

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

3. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

SCHEDULE OF PROPERTY AND EQUIPMENT

	July 31, 2022			October 31, 2021
Laboratory equipment	$	179		$	179
Computer equipment		241			241
Total property and equipment		420			420
Accumulated depreciation		(347	)		(302	)
Net property and equipment	$	73		$	118

Depreciation expense for the three months ended July 31, 2022 and 2021 was approximately $13,000 and $50,000, respectively. Depreciation expense for the nine months ended July 31, 2022 and 2021 was approximately $45,000 and $366,000, respectively. During the nine months ended July 31, 2021, the Company incurred a loss on disposal of equipment of approximately $1,530,000, $968,000 of which is reflected in the research and development expenses and $562,000 of which is reflected in the general and administrative expenses in the condensed consolidated statement of operations.

INTANGIBLE ASSETS

9 Months Ended

Jul. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

SUMMARY OF INTANGIBLE ASSETS

	July 31, 2022			October 31, 2021

Patents	$	275		$	4,836
License		44			777
Software		98			98
Total intangibles		417			5,711
Accumulated amortization		(236	)		(2,357	)
Intangible assets	$	181		$	3,354

The expiration dates of the existing patents range from 2022 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $29,000 and $21,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the three months ended July 31, 2022 and 2021, respectively. Patent applications having a net book value of approximately $159,000 and $90,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the nine months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $70,000 and $68,000 for the three months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $210,000 and $203,000 for the nine months ended July 31, 2022 and 2021, respectively.

Management reviews its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents related to ADXS-HPV (AXAL), ADXS-HOT, ADXS-PSA, ADXS-HER2 and other products that are in development, and the Lm technology licensed from the University of Pennsylvania. There are various scenarios under which an impairment charge may be recorded, which include if a competitor were to gain FDA approval for a similar treatment before the Company, if future clinical trials fail to meet the targeted endpoints, or if a drug application is rejected or fails to be issued. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

During the three months ended July 31, 2022, the Company identified the following indicators of impairment under ASC 360 indicating that the patents and license carrying amounts might not be recoverable:

	●	Adverse changes in the business climate for biotechnology companies, particularly raising capital; and
	●	A significant reduction in the Company’s market capitalization during the nine months ended July 31, 2022.

The Company performed an impairment test under ASC 350 on its patents owned and in-licensed intellectual property. Under this test a fair value of the relevant asset is compared with the carrying amount of such asset. Fair value is calculated using a discounted cash flow analysis. Cash flows are discounted using a weighted average cost of capital derived from comparable companies, which reflects the costs of borrowing as well as the associated risk. The results of the impairment test indicated that the carrying value of the patents owned and in-licensed intellectual property exceeded the fair value. During the three months ended July 31, 2022, the Company recorded an impairment charge for patents owned and in-licensed intellectual property of approximately $3,005,000 in its condensed consolidated statement of operations.

As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2022 (Remaining)	$	24
2023		94
2024		63
Total	$	181

ACCRUED EXPENSES

9 Months Ended

Jul. 31, 2022

Payables and Accruals [Abstract]

ACCRUED EXPENSES

5. ACCRUED EXPENSES:

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

SUMMARY OF ACCRUED EXPENSES

	July 31, 2022		October 31, 2021

Salaries and other compensation	$	116	$	55
Vendors		851		1,968
Professional fees		343		613
Other		200		200
Total accrued expenses	$	1,510	$	2,836

LEASES

9 Months Ended

Jul. 31, 2022

Leases

LEASES

6. LEASES

Operating Leases

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4,512,000 and lease liability of approximately $5,628,000. After consideration of the termination payment and write off of the remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $116,000.

On March 25, 2021, the Company entered into a new one-year lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. This lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeded one-year, the lease no longer qualified for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

Supplemental balance sheet information related to leases was as follows (in thousands):

	July 31, 2022		October 31, 2021
Operating leases:
Operating lease right-of-use assets	$	19	$	40

Operating lease liability	$	19	$	28
Operating lease liability, net of current portion		-		12
Total operating lease liabilities	$	19	$	40

Supplemental lease expense related to leases was as follows (in thousands):

SCHEDULE OF LEASE EXPENSES

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended July 31, 2022		For the Nine Months Ended July 31, 2022
Operating lease cost	General and administrative	$	7	$	22
Variable lease cost	General and administrative		17		36
Total lease expense		$	24	$	58

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended July 31, 2021		For the nine Months Ended July 31, 2021
Operating lease cost	General and administrative	$	-	$	1,301
Short-term lease cost	General and administrative		12		16
Variable lease cost	General and administrative		4		165
Total lease expense		$	16	$	1,482

Other information related to leases where the Company is the lessee is as follows:

	July 31, 2022			October 31, 2021
Weighted-average remaining lease term	0.7 years			1.4 years
Weighted-average discount rate		3.79	%		3.79	%

Supplemental cash flow information related to operating leases was as follows:

For the Nine

Months Ended

July 31, 2022

For the Nine

Months Ended

July 31, 2021

Cash paid for operating lease liabilities

1,363

Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:


Fiscal Year ending October 31,
2022 (Remaining)	$	7
2023		13
Total minimum lease payments		20
Less: Imputed interest		1
Total	$	19

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

9 Months Ended

Jul. 31, 2022

Common Stock Purchase Warrants And Warrant Liability

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of July 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 377,818 shares of our common stock with exercise prices ranging from $20.00 to $224.00 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	20.00		879	September 2024	September 2018 Public Offering
$	224.00		4,092	July 2024	July 2019 Public Offering
$	28.00		57,230	November 2025	November 2020 Public Offering
$	56.00		140,552	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	56.00		175,065	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		377,818

As of July 31, 2022 and October 31, 2021, the Company had 201,874 of its total 377,818 outstanding warrants classified as equity (equity warrants).

Warrant Liability

As of July 31, 2022 and October 31, 2021, the Company had 175,944 of its total 377,818 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of July 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

	July 31, 2022			October 31, 2021
Exercise Price	$	56.00		$	56.00
Stock Price	$	3.73		$	38.80
Expected Term		5.00 years			5.00 years
Volatility %		112	%		106	%
Risk Free Rate		2.70	%		1.18	%

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of July 31, 2022, the down round feature was triggered four times and the exercise price of the warrants were reduced from $1,800.00 to $20.00. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

	July 31, 2022			October 31, 2021
Exercise Price	$	20.00		$	24.00
Stock Price	$	3.73		$	38.80
Expected Term		2.12 years			2.87 years
Volatility %		104	%		123	%
Risk Free Rate		2.89	%		0.77	%

At July 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $287,000 and $4,929,000, respectively. For the three months ended July 31, 2022 and 2021, the Company reported income of approximately $276,000 and $846,000, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2022 and 2021, the Company reported income of approximately $4,642,000 and $1,814,000, respectively, due to changes in the fair value of the warrant liability.

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Jul. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

Atachbarian

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

Purported Stockholder Claims Related to Biosight Transaction

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made settlement demands. On May 20, 2022, the Company and one of the plaintiffs have reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations. The Company believes it has adequately accrued for settlements with the other five shareholders, which is recorded in accrued expenses in the condensed consolidated balance sheet.

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions. Certain stockholders also demanded books and records of the Company pursuant to Delaware law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

Purported Stockholder Claims Related to Series D Convertible Preferred Stock Offering

On February 17, 2022, the Company received a letter on behalf of purported stockholders of the Company, demanding certain books and records pursuant to Delaware law regarding the proposed issuance of super voting preferred stock. The Company agreed to provide certain books and records to the stockholders and agreed to make, and did make, a supplemental disclosure to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

TEMPORARY EQUITY

9 Months Ended

Jul. 31, 2022

Temporary Equity

TEMPORARY EQUITY

9. TEMPORARY EQUITY

Series D Convertible Preferred Stock Offering

On January 31, 2022, the Company consummated an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (the “Series D Preferred Stock”). The shares, which have since been redeemed in accordance with their terms as described below, and are thus no longer outstanding as of July 31, 2022, had an aggregate stated value of $5,000,000. Each share of the Series D preferred stock had a purchase price of $4.75, representing an original issue discount of 5% of the stated value. The shares of Series D Preferred Stock were convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $20.00 per share. The conversion, at the option of the stockholder, could occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company was permitted to compel conversion of the Series D Preferred Stock after the fulfillment of certain conditions and subject to certain limitations. The Series D Preferred Stock also had a liquidation preference over the shares of common stock, and could be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million.

Since the Series D preferred stock had a redemption feature at the option of the holder, it was classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

On April 6, 2022, the holders of all 1,000,000 outstanding shares of the Series D Preferred Stock exercised their right to cause the Company to redeem all of such shares at a price per share equal to 105% of the stated value per share of $5.00, and such shares were redeemed accordingly. The $1,025,000 accretion of the Series D convertible preferred stock to its redemption value was recorded as a reduction in additional paid-in capital (see Note 10).

Preferred Stock Redemption Liability

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

	April 6, 2022			January 31, 2022
Exercise Price	$	20.00		$	20.00
Stock Price	$	9.04		$	10.88
Volatility %		96	%		105	%
Risk Free Rate		1.25	%		1.00	%

At April 6, 2022 and January 31, 2022, the fair value of the preferred stock redemption liability was approximately $44,000 and $87,000, respectively. On April 6, 2022, the Series D convertible preferred stock was redeemed, and the $44,000 preferred stock redemption liability was reclassified into other paid-in capital (see Note 10). For the three months and nine months ended July 31, 2022, the Company reported income of approximately $0 and $44,000, respectively, due to a change in the fair value of the preferred stock redemption liability.

STOCKHOLDERS’ EQUITY

9 Months Ended

Jul. 31, 2022

Equity [Abstract]

STOCKHOLDERS’ EQUITY

10. STOCKHOLDERS’ EQUITY

A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):

SUMMARY OF STOCKHOLDERS EQUITY

	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		975,897	$	2	$	440,916	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		383,333		-		8,550		-			8,550
Warrant exercises		-		-		92,375		-		2,586		-			2,586
Net loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		1,451,605	$	2	$	452,288	$	(414,715	)	$	37,575
Stock-based compensation		-		-		69		-		215		-			215
Stock option exercises		-		-		4		-		-		-			-
Advaxis public offerings, net of offering costs		-		-		230,794		-		13,683		-			13,683
Warrant exercises		-		-		137,968		-		1,185		-			1,185
Issuance of shares to employees under ESPP Plan		-		-		12		-		-		-			-
Net loss		-		-		-		-		-		(5,107	)		(5,107	)
Balance at April 30, 2021		-	$	-		1,820,452	$	2	$	467,371	$	(419,822	)	$	47,551
Stock-based compensation		-		-		-		-		60		-			60
Net loss		-		-		-		-		-		(3,334	)		(3,334	)
Balance at July 31, 2021		-	$	-		1,820,452	$	2	$	467,431	$	(423,156	)	$	44,277

	Preferred Stock				Common Stock					Additional Paid-In			Accumulated			Total Shareholders’
	Shares		Amount		Shares			Amount		Capital			Deficit			Equity
Balance at November 1, 2021		-	$	-		1,820,452		$	2	$	467,486		$	(428,600	)	$	38,888
Stock-based compensation		-		-		-			-		26			-			26
Net loss		-		-		-			-		-			(365	)		(365	)
Balance at January 31, 2022		-	$	-		1,820,452		$	2	$	467,512		$	(428,965	)	$	38,549
Stock-based compensation		-		-		-			-		23			-			23
Accretion of discount and redemption feature of convertible preferred stock		-		-		-			-		(1,025	)		-			(1,025	)
Convertible preferred stock redemption		-		-		-			-		44			-			44
Net loss		-		-		-			-		-			(2,440	)		(2,440	)
Balance at April 30, 2022		-	$	-		1,820,452		$	2	$	466,554		$	(431,405	)	$	35,151
Beginning balance		-	$	-		1,820,452		$	2	$	466,554		$	(431,405	)	$	35,151
Stock-based compensation		-		-		-			-		25			-			25
Fractional shares cashed out		-		-		(4,501	)		-		(18	)		-			(18	)
Net loss		-		-		-			-		-			(6,963	)		(6,963	)
Balance at July 31, 2022		-		-		1,815,951			2		466,561			(438,368	)		28,195
Ending balance		-		-		1,815,951			2		466,561			(438,368	)		28,195

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

SHARE BASED COMPENSATION

9 Months Ended

Jul. 31, 2022

Share-Based Payment Arrangement [Abstract]

SHARE BASED COMPENSATION

11. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

	2022		2021		2022		2021
	Three Months Ended July 31,				Nine Months Ended July 31,
	2022		2021		2022		2021
Research and development	$	12	$	29	$	36	$	142
General and administrative		13		31		38		369
Total	$	25	$	60	$	74	$	511

Stock Options

A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:

SUMMARY OF CHANGES IN STOCK OPTION PLAN

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2021		11,192		$	1,550.26		7.80	$	34
Cancelled or expired		(74	)		22,200.00
Outstanding as of July 31, 2022		11,118		$	1,412.82		7.06	$	-
Vested and exercisable at July 31, 2022		7,490		$	2,077.20		6.64	$	-

The following table summarizes information about the outstanding and exercisable options at July 31, 2022:

Options Outstanding							Options Exercisable
			Weighted		Weighted				Weighted		Weighted
			Average		Average				Average		Average
Exercise	Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range	Outstanding		Contractual		Price		Exercisable		Contractual		Price
$ 24.00-$50.00		4,241		7.86	$	32.53		1,964		7.69	$	30.40
$ 50.01-$100.00		4,174		7.74	$	53.33		2,824		7.73	$	53.58
$ 100.01-20,664.00		2,703		4.75	$	5,677.84		2,703		4.75	$	5,677.84

As of July 31, 2022, there was approximately $77,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 0.94 years.

Potential Acceleration of Stock Options

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 624 unvested stock options as of July 31, 2022, pursuant to his employment agreement, would accelerate.

LICENSING AGREEMENTS

9 Months Ended

Jul. 31, 2022

Licensing Agreements

LICENSING AGREEMENTS

12. LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue. The Company therefore transferred, and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

In April 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans and recorded $1,375,000 in revenue. The Company received the amount due from OS Therapies of $1,375,000 in May 2021.

Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the nine months ended July 31, 2022 and 2021, the Company recorded $250,000 in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

FAIR VALUE

9 Months Ended

Jul. 31, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):

	Level 1		Level 2		Level 3		Total
Fair Value Measured at July 31, 2022
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,183	$	-	$	-	$	17,183
Total Financial Assets at Fair Value	$	17,183	$	-	$	-	$	17,183

Financial liabilities at fair value:
Common stock warrant liability, warrants exercisable at $20.00 through September 2024	$	-	$	-	$	2	$	2
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		285		285
Total financial liabilities at fair value	$	-	$	-	$	287	$	287

	Level 1		Level 2		Level 3		Total
Fair Value Measured at October 31, 2021
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,153	$	-	$	-	$	17,153
Total Financial Assets at Fair Value	$	17,153	$	-	$	-	$	17,153

Financial liabilities at fair value:
Common stock warrant liability, warrants exercisable at $24.00 through September 2024	$	-	$	-	$	27	$	27
Common stock warrant liability, warrants exercisable	$	-	$	-	$	27	$	27
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		4,902		4,902
Total financial liabilities at fair value	$	-	$	-	$	4,929	$	4,929

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the nine months ended July 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.


	Preferred Stock Redemption Liability			Warrant Liabilities			Total
Fair value at October 31, 2021	$	-		$	4,929		$	4,929
Additions		87			-			87
Change in fair value		(43	)		(4,642	)		(4,685	)
Redemption		(44	)		-			(44	)
Fair value at July 31, 2022	$	-		$	287		$	287

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)

9 Months Ended

Jul. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation/Estimates

Basis of Presentation/Estimates

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

Restricted Cash

Restricted Cash

Convertible Preferred Stock

Convertible Preferred Stock

Derivative Financial Instruments

Derivative Financial Instruments

Net Income (Loss) per Share

Net Income (Loss) per Share

	2022		2021
	As of July 31,
	2022		2021
Warrants		377,818		377,818
Stock options		11,118		12,892
Total		388,936		390,710

Reverse Stock Split

Reverse Stock Split

Recent Accounting Standards

Recent Accounting Standards

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)

9 Months Ended

Jul. 31, 2022

Accounting Policies [Abstract]

SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE

	2022		2021
	As of July 31,
	2022		2021
Warrants		377,818		377,818
Stock options		11,118		12,892
Total		388,936		390,710

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Jul. 31, 2022

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

SCHEDULE OF PROPERTY AND EQUIPMENT

	July 31, 2022			October 31, 2021
Laboratory equipment	$	179		$	179
Computer equipment		241			241
Total property and equipment		420			420
Accumulated depreciation		(347	)		(302	)
Net property and equipment	$	73		$	118

INTANGIBLE ASSETS (Tables)

9 Months Ended

Jul. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

SUMMARY OF INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

SUMMARY OF INTANGIBLE ASSETS

	July 31, 2022			October 31, 2021

Patents	$	275		$	4,836
License		44			777
Software		98			98
Total intangibles		417			5,711
Accumulated amortization		(236	)		(2,357	)
Intangible assets	$	181		$	3,354

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS

As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2022 (Remaining)	$	24
2023		94
2024		63
Total	$	181

ACCRUED EXPENSES (Tables)

9 Months Ended

Jul. 31, 2022

Payables and Accruals [Abstract]

SUMMARY OF ACCRUED EXPENSES

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

SUMMARY OF ACCRUED EXPENSES

	July 31, 2022		October 31, 2021

Salaries and other compensation	$	116	$	55
Vendors		851		1,968
Professional fees		343		613
Other		200		200
Total accrued expenses	$	1,510	$	2,836

LEASES (Tables)

9 Months Ended

Jul. 31, 2022

Leases

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES

Supplemental balance sheet information related to leases was as follows (in thousands):

	July 31, 2022		October 31, 2021
Operating leases:
Operating lease right-of-use assets	$	19	$	40

Operating lease liability	$	19	$	28
Operating lease liability, net of current portion		-		12
Total operating lease liabilities	$	19	$	40

SCHEDULE OF LEASE EXPENSES

Supplemental lease expense related to leases was as follows (in thousands):

SCHEDULE OF LEASE EXPENSES

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended July 31, 2022		For the Nine Months Ended July 31, 2022
Operating lease cost	General and administrative	$	7	$	22
Variable lease cost	General and administrative		17		36
Total lease expense		$	24	$	58

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended July 31, 2021		For the nine Months Ended July 31, 2021
Operating lease cost	General and administrative	$	-	$	1,301
Short-term lease cost	General and administrative		12		16
Variable lease cost	General and administrative		4		165
Total lease expense		$	16	$	1,482

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

Other information related to leases where the Company is the lessee is as follows:

	July 31, 2022			October 31, 2021
Weighted-average remaining lease term	0.7 years			1.4 years
Weighted-average discount rate		3.79	%		3.79	%

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES

Supplemental cash flow information related to operating leases was as follows:

For the Nine

Months Ended

July 31, 2022

For the Nine

Months Ended

July 31, 2021

Cash paid for operating lease liabilities

1,363

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES

Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:


Fiscal Year ending October 31,
2022 (Remaining)	$	7
2023		13
Total minimum lease payments		20
Less: Imputed interest		1
Total	$	19

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)

9 Months Ended

Jul. 31, 2022

Subsidiary, Sale of Stock [Line Items]

SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	20.00		879	September 2024	September 2018 Public Offering
$	224.00		4,092	July 2024	July 2019 Public Offering
$	28.00		57,230	November 2025	November 2020 Public Offering
$	56.00		140,552	April 2026	April 2021 Registered Direct Offering (Accompanying Warrants)
$	56.00		175,065	5 years after the date such warrants become exercisable, if ever	April 2021 Private Placement (Private Placement Warrants)
	Grand Total		377,818

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

	July 31, 2022			October 31, 2021
Exercise Price	$	20.00		$	24.00
Stock Price	$	3.73		$	38.80
Expected Term		2.12 years			2.87 years
Volatility %		104	%		123	%
Risk Free Rate		2.89	%		0.77	%

Private Placement [Member]

Subsidiary, Sale of Stock [Line Items]

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

	July 31, 2022			October 31, 2021
Exercise Price	$	56.00		$	56.00
Stock Price	$	3.73		$	38.80
Expected Term		5.00 years			5.00 years
Volatility %		112	%		106	%
Risk Free Rate		2.70	%		1.18	%

TEMPORARY EQUITY (Tables)

9 Months Ended

Jul. 31, 2022

Temporary Equity

SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY

In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

	April 6, 2022			January 31, 2022
Exercise Price	$	20.00		$	20.00
Stock Price	$	9.04		$	10.88
Volatility %		96	%		105	%
Risk Free Rate		1.25	%		1.00	%

STOCKHOLDERS’ EQUITY (Tables)

9 Months Ended

Jul. 31, 2022

Equity [Abstract]

SUMMARY OF STOCKHOLDERS EQUITY

A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):

SUMMARY OF STOCKHOLDERS EQUITY

	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		975,897	$	2	$	440,916	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		383,333		-		8,550		-			8,550
Warrant exercises		-		-		92,375		-		2,586		-			2,586
Net loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		1,451,605	$	2	$	452,288	$	(414,715	)	$	37,575
Stock-based compensation		-		-		69		-		215		-			215
Stock option exercises		-		-		4		-		-		-			-
Advaxis public offerings, net of offering costs		-		-		230,794		-		13,683		-			13,683
Warrant exercises		-		-		137,968		-		1,185		-			1,185
Issuance of shares to employees under ESPP Plan		-		-		12		-		-		-			-
Net loss		-		-		-		-		-		(5,107	)		(5,107	)
Balance at April 30, 2021		-	$	-		1,820,452	$	2	$	467,371	$	(419,822	)	$	47,551
Stock-based compensation		-		-		-		-		60		-			60
Net loss		-		-		-		-		-		(3,334	)		(3,334	)
Balance at July 31, 2021		-	$	-		1,820,452	$	2	$	467,431	$	(423,156	)	$	44,277

	Preferred Stock				Common Stock					Additional Paid-In			Accumulated			Total Shareholders’
	Shares		Amount		Shares			Amount		Capital			Deficit			Equity
Balance at November 1, 2021		-	$	-		1,820,452		$	2	$	467,486		$	(428,600	)	$	38,888
Stock-based compensation		-		-		-			-		26			-			26
Net loss		-		-		-			-		-			(365	)		(365	)
Balance at January 31, 2022		-	$	-		1,820,452		$	2	$	467,512		$	(428,965	)	$	38,549
Stock-based compensation		-		-		-			-		23			-			23
Accretion of discount and redemption feature of convertible preferred stock		-		-		-			-		(1,025	)		-			(1,025	)
Convertible preferred stock redemption		-		-		-			-		44			-			44
Net loss		-		-		-			-		-			(2,440	)		(2,440	)
Balance at April 30, 2022		-	$	-		1,820,452		$	2	$	466,554		$	(431,405	)	$	35,151
Beginning balance		-	$	-		1,820,452		$	2	$	466,554		$	(431,405	)	$	35,151
Stock-based compensation		-		-		-			-		25			-			25
Fractional shares cashed out		-		-		(4,501	)		-		(18	)		-			(18	)
Net loss		-		-		-			-		-			(6,963	)		(6,963	)
Balance at July 31, 2022		-		-		1,815,951			2		466,561			(438,368	)		28,195
Ending balance		-		-		1,815,951			2		466,561			(438,368	)		28,195

SHARE BASED COMPENSATION (Tables)

9 Months Ended

Jul. 31, 2022

Share-Based Payment Arrangement [Abstract]

SUMMARY OF SHARE BASED COMPENSATION EXPENSE

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

	2022		2021		2022		2021
	Three Months Ended July 31,				Nine Months Ended July 31,
	2022		2021		2022		2021
Research and development	$	12	$	29	$	36	$	142
General and administrative		13		31		38		369
Total	$	25	$	60	$	74	$	511

SUMMARY OF CHANGES IN STOCK OPTION PLAN

A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:

SUMMARY OF CHANGES IN STOCK OPTION PLAN

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2021		11,192		$	1,550.26		7.80	$	34
Cancelled or expired		(74	)		22,200.00
Outstanding as of July 31, 2022		11,118		$	1,412.82		7.06	$	-
Vested and exercisable at July 31, 2022		7,490		$	2,077.20		6.64	$	-

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS

The following table summarizes information about the outstanding and exercisable options at July 31, 2022:

Options Outstanding							Options Exercisable
			Weighted		Weighted				Weighted		Weighted
			Average		Average				Average		Average
Exercise	Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range	Outstanding		Contractual		Price		Exercisable		Contractual		Price
$ 24.00-$50.00		4,241		7.86	$	32.53		1,964		7.69	$	30.40
$ 50.01-$100.00		4,174		7.74	$	53.33		2,824		7.73	$	53.58
$ 100.01-20,664.00		2,703		4.75	$	5,677.84		2,703		4.75	$	5,677.84

FAIR VALUE (Tables)

9 Months Ended

Jul. 31, 2022

Fair Value Disclosures [Abstract]

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):

	Level 1		Level 2		Level 3		Total
Fair Value Measured at July 31, 2022
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,183	$	-	$	-	$	17,183
Total Financial Assets at Fair Value	$	17,183	$	-	$	-	$	17,183

Financial liabilities at fair value:
Common stock warrant liability, warrants exercisable at $20.00 through September 2024	$	-	$	-	$	2	$	2
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		285		285
Total financial liabilities at fair value	$	-	$	-	$	287	$	287

	Level 1		Level 2		Level 3		Total
Fair Value Measured at October 31, 2021
	Level 1		Level 2		Level 3		Total
Financial assets at fair value:
Cash equivalents (money market funds)	$	17,153	$	-	$	-	$	17,153
Total Financial Assets at Fair Value	$	17,153	$	-	$	-	$	17,153

Financial liabilities at fair value:
Common stock warrant liability, warrants exercisable at $24.00 through September 2024	$	-	$	-	$	27	$	27
Common stock warrant liability, warrants exercisable	$	-	$	-	$	27	$	27
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)		-		-		4,902		4,902
Total financial liabilities at fair value	$	-	$	-	$	4,929	$	4,929

SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS


	Preferred Stock Redemption Liability			Warrant Liabilities			Total
Fair value at October 31, 2021	$	-		$	4,929		$	4,929
Additions		87			-			87
Change in fair value		(43	)		(4,642	)		(4,685	)
Redemption		(44	)		-			(44	)
Fair value at July 31, 2022	$	-		$	287		$	287

NATURE OF OPERATIONS (Details Narrative) - USD ($) $ in Thousands	Jul. 31, 2022	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents, at carrying value	$ 28,150	$ 41,614

SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	388,936	390,710
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	377,818	377,818
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	11,118	12,892

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative)	Jan. 31, 2022 USD ($)
Series D Preferred Stock Redemption [Member]
Restricted cash	$ 5,250,000

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jul. 31, 2022	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
Laboratory equipment	$ 179	$ 179
Computer equipment	241	241
Total property and equipment	420	420
Accumulated depreciation	(347)	(302)
Net property and equipment	$ 73	$ 118

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Depreciation expense	$ 13,000	$ 50,000	$ 45,000	$ 366,000
Gain loss on sale of property plant equipment				1,530,000
Research And Development [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Gain loss on sale of property plant equipment				968,000
General and Administrative Expense [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Gain loss on sale of property plant equipment				$ 562,000

SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Jul. 31, 2022	Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 275	$ 4,836
License	44	777
Software	98	98
Total intangibles	417	5,711
Accumulated amortization	(236)	(2,357)
Intangible assets	$ 181	$ 3,354

SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Jul. 31, 2022	Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (Remaining)	$ 24
2023	94
2024	63
Intangible assets	$ 181	$ 3,354

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Goodwill [Line Items]
Book value patent applications, net			$ 159,000	$ 90,000
Intangible asset amortization expense			210,000	203,000
Asset impairment charges	$ 3,005,000		3,005,000
General and Administrative Expense [Member]
Goodwill [Line Items]
Book value patent applications, net	29,000	21,000	159,000	90,000
Intangible asset amortization expense	$ 70,000	$ 68,000	$ 210,000	$ 203,000

SUMMARY OF ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jul. 31, 2022	Oct. 31, 2021
Payables and Accruals [Abstract]
Salaries and other compensation	$ 116	$ 55
Vendors	851	1,968
Professional fees	343	613
Other	200	200
Total accrued expenses	$ 1,510	$ 2,836

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) - USD ($)	Jul. 31, 2022	Oct. 31, 2021	Mar. 26, 2021	Mar. 25, 2021
Leases
Operating lease right-of-use assets	$ 19,000	$ 40,000	$ 4,512,000	$ 43,000
Operating lease liability	19,000	28,000
Operating lease liability, net of current portion		12,000
Total operating lease liabilities	$ 19,000	$ 40,000	$ 5,628,000	$ 43,000

SCHEDULE OF LEASE EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Total lease expense	$ 24	$ 16	$ 58	$ 1,482
General and Administrative Expense [Member]
Operating lease cost	7		22	1,301
Variable lease cost	$ 17	4	$ 36	165
Short-term lease cost		$ 12		$ 16

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)	Jul. 31, 2022	Oct. 31, 2021
Leases
Weighted-average remaining lease term	8 months 12 days	1 year 4 months 24 days
Weighted-average discount rate	3.79%	3.79%

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Leases
Cash paid for operating lease liabilities	$ 22	$ 1,363

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) - USD ($)	Jul. 31, 2022	Oct. 31, 2021	Mar. 26, 2021	Mar. 25, 2021
Leases
2022 (Remaining)	$ 7,000
2023	13,000
Total minimum lease payments	20,000
Less: Imputed interest	1,000
Total	$ 19,000	$ 40,000	$ 5,628,000	$ 43,000

LEASES (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
LEASES (Details Narrative) - USD ($)	Mar. 26, 2021	Mar. 25, 2021	Jul. 31, 2022	Oct. 31, 2021
Leases
Lease expiration date			November 2025
Lease termination	$ 1,000,000
Security deposit	182,000
Net payment for termination fee	818,000
Operating lease, right of use asset	4,512,000	$ 43,000	$ 19,000	$ 40,000
Operating lease liability	5,628,000	43,000	$ 19,000	$ 40,000
Net gain on leases	$ 116,000
Payment of rent		$ 29,000
Lessee finance lease renewal term date		Mar. 25, 2023

SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2022	Oct. 31, 2021
Offsetting Assets [Line Items]
Exercise Price	$ 20.00	$ 24.00
Grand Total Number of Shares Underlying Warrants	377,818	377,818
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 20.00	$ 20.00
Grand Total Number of Shares Underlying Warrants	879	879
Expiration Date	September 2024	September 2024
Type of financing	September 2018 Public Offering	September 2018 Public Offering
Exercise Price Range Two [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 224.00	$ 224.00
Grand Total Number of Shares Underlying Warrants	4,092	4,092
Expiration Date	July 2024	July 2024
Type of financing	July 2019 Public Offering	July 2019 Public Offering
Exercise Price Range Three [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 28.00	$ 28.00
Grand Total Number of Shares Underlying Warrants	57,230	57,230
Expiration Date	November 2025	November 2025
Type of financing	November 2020 Public Offering	November 2020 Public Offering
Exercise Price Range Four [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 56.00	$ 56.00
Grand Total Number of Shares Underlying Warrants	140,552	140,552
Expiration Date	April 2026	April 2026
Type of financing	April 2021 Registered Direct Offering (Accompanying Warrants)	April 2021 Registered Direct Offering (Accompanying Warrants)
Exercise Price Range Five [Member]
Offsetting Assets [Line Items]
Exercise Price	$ 56.00	$ 56.00
Grand Total Number of Shares Underlying Warrants	175,065	175,065
Expiration Date	5 years after the date such warrants become exercisable, if ever	5 years after the date such warrants become exercisable, if ever
Type of financing	April 2021 Private Placement (Private Placement Warrants)	April 2021 Private Placement (Private Placement Warrants)

SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)	Jul. 31, 2022 $ / shares	Oct. 31, 2021 $ / shares
Exercise Price	$ 20.00	$ 24.00
Private Placement [Member]
Exercise Price	56.00	56.00
Warrant Liability [Member]
Exercise Price	20.00	24.00
Stock Price	$ 3.73	$ 38.80
Warrant Liability [Member] \| Measurement Input, Expected Term [Member]
Expected Term	2 years 1 month 13 days	2 years 10 months 13 days
Warrant Liability [Member] \| Measurement Input, Price Volatility [Member]
Measurement input percentage	104	123
Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage	2.89	0.77
Warrant Liability [Member] \| Private Placement [Member]
Exercise Price	$ 56.00	$ 56.00
Stock Price	$ 3.73	$ 38.80
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Expected Term [Member]
Expected Term	5 years	5 years
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Price Volatility [Member]
Measurement input percentage	112	106
Warrant Liability [Member] \| Private Placement [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage	2.70	1.18

COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021	Oct. 31, 2021	Jun. 03, 2021	May 01, 2021	Apr. 30, 2021
Number of warrants to purchase common stock	377,818		377,818		377,818
Warrant exercise price per share	$ 20.00		$ 20.00		$ 24.00
Common stock, par value	$ 0.001		$ 0.001		$ 0.001			$ 0.001
Common stock shares authorized	170,000,000		170,000,000		170,000,000		300,000,000	170,000,000
Fair value of the warrant liability	$ 287,000		$ 287,000		$ 4,929,000
Income on fair value of warrants	$ 276,000	$ 846,000	$ 4,642,000	$ 1,814,000
Private Placement [Member]
Warrant exercise price per share	$ 56.00		$ 56.00		$ 56.00
Minimum [Member]
Common stock shares authorized						170,000,000
Maximum [Member]
Common stock shares authorized						300,000,000
Warrant [Member]
Warrants outstanding	377,818		377,818		377,818
Number of warrants to purchase common stock	377,818		377,818		377,818
Warrant [Member] \| Minimum [Member]
Warrant exercise price per share	$ 20.00		$ 20.00		$ 20.00
Warrant [Member] \| Maximum [Member]
Warrant exercise price per share	$ 224.00		$ 224.00		$ 224.00
Equity Warrants [Member]
Warrants outstanding	377,818		377,818		377,818
Number of warrants to purchase common stock	201,874		201,874		201,874
Warrant Liability [Member]
Warrant exercise price per share	$ 20.00		$ 20.00		$ 24.00
Warrant Liability [Member] \| Private Placement [Member]
Warrants outstanding	377,818		377,818		377,818
Number of warrants to purchase common stock	175,944		175,944		175,944
Warrant exercise price per share	$ 56.00		$ 56.00		$ 56.00
Warrant Liability [Member] \| Minimum [Member]
Warrant exercise price per share	20.00		20.00
Warrant Liability [Member] \| Maximum [Member]
Warrant exercise price per share	$ 1,800.00		$ 1,800.00

SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)	Apr. 06, 2022	Jan. 31, 2022
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	20.00	20.00
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	9.04	10.88
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	96	105
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input percentage	1.25	1.00

TEMPORARY EQUITY (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended			9 Months Ended
TEMPORARY EQUITY (Details Narrative) - USD ($)	Apr. 06, 2022	Jan. 31, 2022	Jul. 31, 2022	Apr. 30, 2021	Jan. 31, 2021	Jul. 31, 2022	Oct. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Stock issued during period value new issues				$ 13,683,000	$ 8,550,000
Issue discount						5.00%
Temporary equity stock stated value accumulated dividends						105.00%
Temporary equity stock stated value accumulated dividends on extension						110.00%
Proceeds from issuance or estimated offering		$ 4,312,000				$ 4,300,000
Temporary equity, carrying amount, attributable to parent		4,225,000
Preferred stock, redemption amount	$ 44,000	$ 87,000
Change in preferred stock, redemption liability amount			$ 0			$ 44,000
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock conversion price			$ 20.00			$ 20.00
Temporary equity stock stated value accumulated dividends	105.00%
Temporary equity shares outstanding	1,000,000
Temporary equity par value	$ 5.00
Series D convertible preferred stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued during period value new issues	$ 1,025,000
Preferred stock, redemption amount	$ 44,000
Private Placement [Member] \| Institutional Investors [Member] \| Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued		1,000,000
Stock issued during period value new issues						$ 5,000,000
Share purchase price			$ 4.75			$ 4.75

SUMMARY OF STOCKHOLDERS EQUITY (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Jul. 31, 2022	Apr. 30, 2022	Jan. 31, 2022	Jul. 31, 2021	Apr. 30, 2021	Jan. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 35,151	$ 38,549	$ 38,888	$ 47,551	$ 37,575	$ 30,180	$ 38,888	$ 30,180
Stock-based compensation	25	23	26	60	215	236
Advaxis public offerings, net of offering costs					13,683	8,550
Warrant exercises					1,185	2,586
Net loss	(6,963)	(2,440)	(365)	(3,334)	(5,107)	(3,977)	(9,768)	(12,418)
Stock option exercises
Issuance of shares to employees under ESPP Plan
Ending balance	28,195	35,151	38,549	44,277	47,551	37,575	28,195	44,277
Accretion of discount and redemption feature of convertible preferred stock		(1,025)
Convertible preferred stock redemption		44
Fractional shares cashed out	(18)						18
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance
Beginning balance, shares
Stock-based compensation
Advaxis public offerings, net of offering costs
Warrant exercises
Net loss
Stock option exercises
Issuance of shares to employees under ESPP Plan
Ending balance
Ending balance, shares
Accretion of discount and redemption feature of convertible preferred stock
Convertible preferred stock redemption
Fractional shares cashed out
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2
Beginning balance, shares	1,820,452	1,820,452	1,820,452	1,820,452	1,451,605	975,897	1,820,452	975,897
Stock-based compensation
Stock-based compensation, shares					69
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares					230,794	383,333
Warrant exercises
Warrant exercises, shares					137,968	92,375
Net loss
Stock option exercises
Stock option exercises, shares					4
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares					12
Ending balance	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2	$ 2
Ending balance, shares	1,815,951	1,820,452	1,820,452	1,820,452	1,820,452	1,451,605	1,815,951	1,820,452
Accretion of discount and redemption feature of convertible preferred stock
Convertible preferred stock redemption
Fractional shares cashed out
Fractional shares cashed out, shares	(4,501)
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 466,554	467,512	$ 467,486	$ 467,371	$ 452,288	$ 440,916	$ 467,486	$ 440,916
Stock-based compensation	25	23	26	60	215	236
Advaxis public offerings, net of offering costs					13,683	8,550
Warrant exercises					1,185	2,586
Net loss
Stock option exercises
Issuance of shares to employees under ESPP Plan
Ending balance	466,561	466,554	467,512	467,431	467,371	452,288	466,561	467,431
Accretion of discount and redemption feature of convertible preferred stock		(1,025)
Convertible preferred stock redemption		44
Fractional shares cashed out	(18)
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(431,405)	(428,965)	(428,600)	(419,822)	(414,715)	(410,738)	(428,600)	(410,738)
Stock-based compensation
Advaxis public offerings, net of offering costs
Warrant exercises
Net loss	(6,963)	(2,440)	(365)	(3,334)	(5,107)	(3,977)
Stock option exercises
Issuance of shares to employees under ESPP Plan
Ending balance	(438,368)	(431,405)	$ (428,965)	$ (423,156)	$ (419,822)	$ (414,715)	$ (438,368)	$ (423,156)
Accretion of discount and redemption feature of convertible preferred stock
Convertible preferred stock redemption
Fractional shares cashed out

SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2022	Jul. 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 25	$ 60	$ 74	$ 511
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	12	29	36	142
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 13	$ 31	$ 38	$ 369

SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Jul. 31, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance \| shares	11,192
Weighted Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 1,550.26
Weighted Average Remaining Contractual Life In Years, Beginning	7 years 9 months 18 days
Aggregate Intrinsic Value, Beginning \| $	$ 34
Shares, Cancelled or Expired \| shares	(74)
Weighted Average Exercise Price, Cancelled or Expired \| $ / shares	$ 22,200.00
Shares, Outstanding, Ending Balance \| shares	11,118
Weighted Average Exercise Price, Outstanding, Ending \| $ / shares	$ 1,412.82
Weighted Average Remaining Contractual Life In Years, Ending Balance	7 years 21 days
Aggregate Intrinsic Value, Ending \| $
Shares, Vested and Exercisable \| shares	7,490
Weighted Average Exercise Price, Vested and Exercisable \| $ / shares	$ 2,077.20
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	6 years 7 months 20 days
Aggregate Intrinsic Value, Vested and Exercisable \| $

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)	9 Months Ended
	Jul. 31, 2022 $ / shares shares
Exercise Price Range One [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	$ 24.00
Exercise Price Range, upper limit	$ 50.00
Number Outstanding, Options Outstanding \| shares	4,241
Weighted Average Remaining Contractual, Options Outstanding	7 years 10 months 9 days
Weighted Average Exercise Price, Options Outstanding	$ 32.53
Number Exercisable, Options Exercisable \| shares	1,964
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	7 years 8 months 8 days
Weighted Average Exercise Price, Options Exercisable	$ 30.40
Exercise Price Range Two [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	50.01
Exercise Price Range, upper limit	$ 100.00
Number Outstanding, Options Outstanding \| shares	4,174
Weighted Average Remaining Contractual, Options Outstanding	7 years 8 months 26 days
Weighted Average Exercise Price, Options Outstanding	$ 53.33
Number Exercisable, Options Exercisable \| shares	2,824
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	7 years 8 months 23 days
Weighted Average Exercise Price, Options Exercisable	$ 53.58
Exercise Price Range Three [Member]
Offsetting Assets [Line Items]
Exercise Price Range, lower limit	100.01
Exercise Price Range, upper limit	$ 20,664.00
Number Outstanding, Options Outstanding \| shares	2,703
Weighted Average Remaining Contractual, Options Outstanding	4 years 9 months
Weighted Average Exercise Price, Options Outstanding	$ 5,677.84
Number Exercisable, Options Exercisable \| shares	2,703
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	4 years 9 months
Weighted Average Exercise Price, Options Exercisable	$ 5,677.84

SHARE BASED COMPENSATION (Details Narrative) $ in Thousands	9 Months Ended
SHARE BASED COMPENSATION (Details Narrative) $ in Thousands	Jul. 31, 2022 USD ($) shares
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Unrecognized compensation cost \| $	$ 77,000
Unrecognized weighted average vesting period	11 months 8 days
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Unvested stock options \| shares	624

LICENSING AGREEMENTS (Details Narrative) - USD ($)				1 Months Ended	9 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Apr. 30, 2021	Apr. 30, 2020	Sep. 04, 2018	May 31, 2021	Jul. 31, 2022	Jul. 31, 2021
Milestone achievement, description					the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue.
Global BioPharma, Inc [Member] \| License and Service [Member]
Revenue					$ 250,000	$ 250,000
Development, License and Supply Agreement [Member] \| OS Therapies [Member]
Revenue	$ 1,375,000	$ 25,000
Funding milestone payment			$ 2,337,500
Funding for milestone payment				$ 1,375,000

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical) - $ / shares	Jul. 31, 2022	Oct. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price per share	$ 20.00	$ 24.00
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price per share	$ 56.00	$ 56.00

SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) $ in Thousands	9 Months Ended
	Jul. 31, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value at October 31, 2021	$ 4,929
Additions	87
Change in fair value	(4,685)
Redemption	(44)
Fair value at July 31, 2022	287
Preferred stock redemption liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value at October 31, 2021
Additions	87
Change in fair value	(43)
Redemption	(44)
Fair value at July 31, 2022
Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value at October 31, 2021	4,929
Additions
Change in fair value	(4,642)
Redemption
Fair value at July 31, 2022	$ 287

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($) $ in Thousands	Jul. 31, 2022	Oct. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value	$ 17,183	$ 17,153
Common stock warrant liability, warrants exercisable	287	4,929
Total financial liabilities at fair value	287	4,929
Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)	285	4,902
Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable	2	27
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)	17,183	17,153
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value	17,183	17,153
Total financial liabilities at fair value
Fair Value, Inputs, Level 1 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 1 [Member] \| Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)	17,183	17,153
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value
Total financial liabilities at fair value
Fair Value, Inputs, Level 2 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 2 [Member] \| Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Financial Assets at Fair Value
Total financial liabilities at fair value	287	4,929
Fair Value, Inputs, Level 3 [Member] \| Private Placement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)	285	4,902
Fair Value, Inputs, Level 3 [Member] \| Through September 2024 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liability, warrants exercisable	2	27
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents (money market funds)